职称：教授，博士生导师，博士后合作导师
通信地址：广州大道北1838号南方医科大学公共卫生学院
E-mail：5942342qq@163.com;a124965468@smu.edu.cn
职务：无
职称级别：正高
最高学历学位：博士
所属科室：三级生物安全实验室
研究方向：人类病原抗体与疫苗
科研项目：
1. H5N6禽流感神经氨酸酶人源抗体筛选与抗病毒机制研究（81902058）,国家自然科学青年基金资助, 2020.01-2022.12, 21万元人民币（主持）。
2. H5N6禽流感血凝素人源抗体活性鉴定与抗病毒机制研究(2019T120147),中国博士后科学基金特别资助, 2018.07-2020.06, 18万元人民币（主持）。
3.识别乙型流感不同抗原表位广谱抗体联合抗病毒研究(2018M641508),中国博士后科学基金二等资助，2018.07-2020.06, 5万元人民币（主持）。
4.乙型流感神经氨酸酶广谱人源抗体筛选与抗病毒机制研究(2020A1515010368),广东省自然科学基金面上项目, 2019.10- 2022.09, 10万元人民币（主持）。
5. H5N6禽流感人源广谱抗体制备及其抗病毒机制研究(JCYJ20190809183205622),深圳市基础研究面上项目，2020.01- 2023.05, 10万元人民币（主持）。
6.通用型流感疫苗—鉴定针对季节性流感病毒的交叉中和性单克隆抗体的合作研究计划，赛诺菲巴斯德公司，2013-2017, 150万美元（参与）。
7.深圳科技创新委员会定向申报项目（202002073000001和202002073000002）, 1000万元人民币（参与）。
8.国家自然科学基金面上项目，甲型流感病毒血凝素头部区跨亚型广谱中和抗体的作用机制研究(81871651)，2019-2022（参与）。
9.国家自然科学基金面上项目，基于广谱中和单抗的通用型流感疫苗设计及其结构基础研究(31670934)，2017-2020（参与）。
10.国家自然科学基金，人肠道病毒71型构象性中和表位的确定及其诱导抗病毒免疫保护应答机制研究(81371817)，2014-2017（参与）。
成果奖励：深圳市科技进步二等奖
代表论文：
1.Chenguang Shen*, Zhaoqin Wang*, Fang Zhao*, Yang Yang*, Jinxiu Li, Jing Yuan, Fuxiang Wang, Delin Li, Minghui Yang, Li Xing, Jinli Wei, Haixia Xiao, Yan Yang, Jiuxin Qu, Ling Qing, Li Chen, Zhixiang Xu, Ling Peng, Yanjie Li, Haixia Zheng, Feng Chen, Kun Huang, Yujing Jiang, Dongjing Liu, Zheng Zhang#, Yingxia Liu#, Lei Liu#. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma [J].Jama,2020 Apr 28;323(16):1582-1589.(共同一作，Article,网站封面，中科院一区Top,IF=51.3, ESI高引论文，ESI热点论文，Web of Science引用613次，谷歌学术引用1460次，2020年JAMA热点论文首位，代表性论文).
2.Yan Wu*, Feiran Wang*,Chenguang Shen*, Weiyu Peng*, Delin Li*, Cheng Zhao, Zhaohui Li, Shihua Li, Yuhai Bi, Yang Yang, Yuhuan Gong, Haixia Xiao, Zheng Fan, Shuguang Tan, Guizhen Wu, Wenjie Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, Jianxun Qi, George Fu Gao#, Feng Gao#, Lei Liu#. A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. (2020).Science,2020 Jun 12;368(6496):1274-1278.(共同一作，Article,中科院一区Top, IF=41.04, ESI高引论文, Web of Science引用110次，谷歌学术引用298次，代表性论文).
3.Chenguang Shen*, Junyu Chen*, Rui Li*, Mengya Zhang*, Guosong Wang*, Svetlana Stegalkina, Limin Zhang, Jing Chen, Jianli Cao, Xingjian Bi1,2, Stephen F. Anderson, Timothy Alefantis, Qingbing Zheng, Mujing Fang, Kunyu Yang, Hai Yu, Wenxin Luo, Zizheng Zheng, Quan Yuan, Jun Zhang, J. Wai-Kuo Shih, Harold Kleanthous, Honglin Chen, Yixin Chen#, Ningshao Xia#. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses [J].Science translational medicine, 2017, 9(412), eaam5752.（共同一作，Article, Science子刊，Nature发表正面评述，中科院一区Top, IF=16.76, Web of Science引用34次，谷歌学术引用42次，代表性论文).
4.Chenguang Shen*,Minwei Zhang*, Yuanzhi Chen*, Limin Zhang, Guosong Wang, Junyu Chen, Siyuan Chen, Zizhen Li, Feixue Wei, Jing Chen, Shuxin Guo, Yujing Wang, Qingbing Zheng, Hai Yu, Wenxin Luo, Jun Zhang, Honglin Chen,Yixin Chen#, Ningshao Xia. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency [J].Theranostics, 2019, 9(1): 210.（共同一作，Article,中科院一区Top, IF=8.54, Web of Science引用9次，谷歌学术引用14次，代表性论文).
5.Yang Yang*,Chenguang Shen*, Jinxiu Li*, Jing Yuan, Jinli Wei, Fengmin Huang, Fuxiang Wang, Guobao Li, Yanjie Li, Li Xing, Ling Peng, Minghui Yang, Mengli Cao, Haixia Zheng, Weibo Wu, Rongrong Zou, Delin Li, Zhixiang Xu, Haiyan Wang, Mingxia Zhang, Zheng Zhang, Chengyu Jiang#, Lei Liu#, Yingxia Liu#. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.J Allergy Clin Immunol. 2020, July; 146(1): 119-127. (共同一作，Article,中科院一区Top, IF=14.11, Web of Science引用69次，谷歌学术引用146次，代表性论文).
6.Yali Zhang*, Shaojuan Wang*, Yangtao Wu*, Wangheng Hou*, Lunzhi Yuan*,Chenguang Shen*, Juan Wang，Jianghui Ye，Qingbing Zheng，Jian Ma，Jingjing Xu，Min Wei，Zonglin Li , Sheng Nian, Hualong Xiong, Liang Zhang, Yang Shi, Baorong Fu, Jiali Cao, Chuanlai Yang, Zhiyong Li, Ting Yang, Lei Liu, Hai Yu, Jianda Hu, Shengxiang Ge Yixin Chen, Tianying Zhang, Jun Zhang, Tong Cheng#, Quan Yuan#, Ningshao Xia#. Virus‐free and live‐cell visualizing SARS‐CoV‐2 cell entry for studies of neutralizing antibodies and compound inhibitors[J].Small Methods, 2020: 2001031. (共同一作，Article,中科院一区Top, IF=12.13, Web of Science引用0次，谷歌学术引用1次)
7.Chuang Liu*, Luiza Mendonça*, Yang Yang*, Yuanzhu Gao*,Chenguang Shen*, Jiwei Liu, Tao Ni, Bin Ju, Congcong Liu, Xian Tang, Jinli Wei, Xiaomin Ma, Yanan Zhu, Weilong Liu, Shuman Xu, Yingxia Liu, Jing Yuan, Jing Wu, Zheng Liu, Zheng Zhang#, Lei Liu#, Peiyi Wang#, Peijun Zhang#. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.Structure. 2020, November 3; 28(11): 1218-1224. (共同一作，Article, Cell子刊，中科院大类二区、小类一区Top, IF=5.237, Web of Science引用0次，谷歌学术引用8次).
8.Yang Yang*,Chenguang Shen*, Jin Li*, Rongrong Zou, Gary Wong, LingPeng, Liuqing Yang, Shisong Fang, Jianming Li, Xiaohe Li, Weibo Wu, XiaoJiang, Lijiao Zeng, Jianfeng Lan, Yuhai Bi, George F. Gao, Jing Yuan#,Yingxia Liu#. Clinical and virological characteristics of human infections with H7N9 avian influenza virus in Shenzhen, China, 2013-2017.J Infect. 2019 Oct;79(4):389-399.（共同一作，Letter, IF=5.08,中科院二区，Web of Science引用1次，谷歌学术引用3次).
9.HuaLong Xiong*, JiaLi Cao*,ChenGuang Shen*, Jian Ma, XiaoYang Qiao, TianShu Shi, ShengXiang Ge, HuiMing Ye, Jun Zhang, Yuan Quan# , TianYing Zhang# and NingShao Xia#. Clinical and virological characteristics of human infections with H7N9 avian influenza virus in Shenzhen, China, 2013-2017.Frontiers in Pharmacology. 2019 Oct;79(4):389-399.（共同一作，Article, IF=4.418,中科院二区，Web of Science引用0次，谷歌学术引用1次).
10.Yanjie Li*,Chenguang Shen*, Liuqing Yang*, Yang Yang, Miao Wang,Shanqin Li, FengChen, Min Yang, Ling Peng, Jinmin Ma,Zhongping Duan#,Liqiang Li#, Yingxia Liu#. Intra-host diversity of hepatitis B virus during mother-to-child transmission: the X gene may play a key role in virus survival in children after transmission.Arch Virol. 2020 Apr 2.（共同一作，Article,中科院四区，IF=2.26，Web of Science引用1次，谷歌学术引用1次).
11.Pengfei Zhang*, Yixin Chen*, Yun Zeng*,Chenguang Shen, Rui Li, Zhide Guo, Shaowei Li,Qingbing Zheng, Chengchao Chu, Zhantong Wang, Zizheng Zheng, Rui Tian, Shengxiang Ge,Xianzhong Zhang, Ning-Shao Xia, GangLiu#, and Xiaoyuan Chen#. Virus-mimetic nanovesicles as a versatile antigen-delivery system [J].PNAS, 2015, 112(45): E6129-E6138.（参与作者，Article,中科院一区Top, IF=9.7).
12.J. Chen*, K. Yang*, M. Zhang#,C. Shen, J.Chen, G. Wang, S. Huang,M. Zhang, H. Xiong, H. Chen, Y. Chen#, N. Xia. Rapid identification of imported influenza viruses at Xiamen International Airport via an active surveillance program [J].Clinical Microbiology and Infection, 2018, 24(3): 289-294.（参与作者，Article,中科院一区Top, IF=5.3).
13.Qingxian Cai*，Minghui Yang*，Dongjing Liu*，Jun Chen*，Dan Shu，Junxia Xia，Xuejiao Liao，Yuanbo Gu，Qiue Cai，Yang Yang，Chenguang Shen，Xiaohe Li，Ling Peng，Deliang Huang，Jing Zhang，Shurong Zhang，Fuxiang Wang，Jiaye Liu，Li Chen，Shuyan Chen，Zhaoqin Wang，Zheng Zhang，Ruiyuan Cao，Wu Zhong#，Yingxia Liu#，LeiLiu#. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study [J].Engineering.（参与作者，Article,中科院一区Top, IF=6.495).
14.Y. Liu*, C. Zhang*, F. Huang*, Y. Yang*, F. Wang, J. Yuan, Z. Zhang, Y. Qin, X. Li, D. Zhao, S. Li, S. Tan, Z. Wang, J. Li,C. Shen,J. Li, L. Peng, W. Wu, M. Cao, L. Xing, Z. Xu, L. Chen, C. Zhou, W. Liu#, L. Liu#, C. Jiang#. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury [J].National Science Review.（参与作者，Article,中科院一区Top, IF=16.693).
15.Peng TT*, Cai QE*, Yang M*, Chen SP, Chen F, Wang M, Peng L, Wong G,Shen CG,Cheng WB, Liu SY, Peng YB, Peng JH, Chen CM, Yang LQ, Tang YM, Xu ZX, Liu YX#. Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates [J]. Archives of virology, 2019, 164(5): 1335-1341.（参与作者，Article,中科院四区，IF=2.26).
16.Gui X*, Li R*, Zhang X,Shen C, Yu H, Guo X, Kang Y, Chen J, Chen H, Chen Y#, Xia N#. An important amino acid in nucleoprotein contributes to influenza A virus replication by interacting with polymerase PB2. [J].Virology,2014 Sep;464-465:11-20.（参与作者，Article,中科院三区，IF=3.2).
17.Jianghong An*, Xuejiao Liao*, Tongyang Xiao*, Shen Qian, Jing Yuan, Haocheng Ye, Furong Qi,Chengguang Shen,Lifei Wang, Yang Liu, Xiaoya Cheng, Na Li, Qingxian Cai, Fang Wang, Jun Chen, Guojun Li, Qiu’e Cai, Yingxia Liu, Yunfang Wang, Feng Zhang, Yang Fu, Qing He, Xiaohua Tan#, Lei Liu#, and Zheng Zhang#. Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test [J].Annals of translational medicine, 2020, 8(17).（参与作者，Article,中科院三区, IF=3.297).
18.Yang Yang*，Minghui Yang*，Jing Yuan*，Fuxiang Wang*，Zhaoqin Wang，Jinxiu Li，Mingxia Zhang，Li Xing，Jinli Wei，Ling Peng，Gary Wong，Haixia Zheng，Weibo Wu，Chenguang Shen，Mingfeng Liao，Kai Feng，Jianming Li，Qianting Yang，Juanjuan Zhao，Lei Liu#，Yingxia Liu#. Laboratory Diagnosis and Monitoring the Viral Shedding of SARS-CoV-2 Infection[J].The Innovation, 2020, 1(3): 100061.（参与作者，Article, Cell旗下新刊).
19.Yang, M*, Wei, J*, Huang, T, Lei, L,Shen, C, Lai, J, Yang, M, Liu, L, Yang, Y#, Liu, G#, & Liu, Y#. (2020). Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells.Phytotherapy research : PTR, 10.1002/ptr.6916. Advance online publication.（参与作者，Letter,中科院二区Top, IF=4.087).
*第一作者/共同第一作者，#通讯作者/共同通讯作者
专利：
1.Chen Yixin,Shen Chenguang,Chen Junyu, Wang Guosong, Zhang Mengya, Xia Ningshao. Broad-spectrum monoclonal anti-flu B antibody and uses thereof. Australian Patent No.: 2016270147, 2018.12.06（澳大利亚专利局授权）。
2.陈毅歆；沈晨光；陈俊煜；王国松；张梦娅；夏宁邵.抗Flu B的广谱单克隆抗体及其用途.授权公告号：CN106243218B.授权公告日：20200515（中国专利局授权）。
3. Yixin Chen, Qingbing Zheng, Rui Li,Chenguang Shen,Shaojun Ke, Wenxin Luo, Honglin Chen, Ningshao Xia. Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus. United States Patent no.: US9650434B2, 2017.5.16（美国专利局授权）。
4.陈毅歆;郑清炳;李睿;沈晨光;柯少君;罗文新;陈鸿霖;夏宁邵.识别流感病毒血凝素蛋白HA1结构域的广谱单克隆抗体.授权公告号：CN104098692B.公告日：2018.11.30（中国专利局授权）。
5.一种抗新型冠状病毒的单克隆抗体及其应用 （申请专利，202010151350.3,第三发明人）
6.一种抗新型冠状病毒的单克隆抗体及其应用（申请专利，202010151348.6,第三发明人）
7.一种抗新型冠状病毒的单克隆抗体及其应用（申请专利，202010191249.0,第三发明人）
8.一种抗新型冠状病毒的单克隆抗体及其应用（申请专利，202010151347.1,第三发明人）
9.一种抗新型冠状病毒的单克隆抗体及其应用 （申请专利，PCT/CN2020/079737,第三发明人）
10.一种抗新型冠状病毒的单克隆抗体及其应用（申请专利，PCT/CN2020/079718,第三发明人）
11. H3N2亚型流感病毒血凝素蛋白的突变体及其应用（申请专利，CN201811176389.X,第二发明人）
12.一种抗独特型抗体及其应用（申请专利，CN201610622352.X,第二发明人）
13. MUTANT OF H3N2 SUBTYPE INFLUENZA VIRUS HEMAGGLUTININ PROTEIN AND USE THEREOF（申请专利，PCT/CN2018/109589；WO/2019/076218；第二发明人）
14. BROAD-SPECTRUM MONOCLONAL ANTI-FLU B ANTIBODY AND USES THEREOF（申请专利，PCT/CN2016/084496；WO/2016/192652；第二发明人）
15.一种用于治疗肿瘤的伪狂犬病毒（申请专利，CN201910102988.5；CN110101723A；第四发明人）
研究领域：
致力于人类病原治疗性、预防性及诊断用抗体和疫苗相关研究，擅长各类抗体筛选鉴定及其抗病原机制研究，含动物源性和人源性抗体；相关研究成果可同时进行转化应用，开发为检测试剂盒、治疗性药物和疫苗等生物制剂产品。